Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Psyence Biomedical Ltd (PBM)

Psyence Biomedical Ltd (PBM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,681
  • Shares Outstanding, K 843
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,160 K
  • EBIT $ 0 M
  • EBITDA $ -3 M
  • 60-Month Beta -0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.51 +110.60%
on 12/18/24
7.87 -59.59%
on 12/19/24
-0.57 (-15.20%)
since 11/20/24
3-Month
1.51 +110.60%
on 12/18/24
10.35 -69.28%
on 10/22/24
-5.81 (-64.64%)
since 09/20/24

Most Recent Stories

More News
Psyence Biomedical Launches Patient Screening for Phase IIb Clinical Trial of Psilocybin in Palliative Care

Psyence Biomedical initiates Phase IIb psilocybin trial for Adjustment Disorder, starting patient randomization in January 2025.Quiver AI SummaryPsyence Biomedical Ltd. has announced significant progress...

PBM : 3.18 (+29.27%)
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

PBM : 3.18 (+29.27%)
Psyence Biomedical Ltd. and Optimi Health Corp. Form Strategic Partnership for GMP-Certified Psilocybin Supply in Palliative Care Initiatives

Psyence Biomedical executed binding agreements with Optimi Health for exclusive psilocybin supply for drug development in palliative care.Quiver AI SummaryPsyence Biomedical Ltd. has announced that it...

PBM : 3.18 (+29.27%)
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

PBM : 3.18 (+29.27%)
Psyence Biomed's Stake in PsyLabs Valued at $2 Million; Company Strengthens Financial Position and Advances Clinical Trials

Psyence Biomed reports $2 million stake in PsyLabs, reduces debt, and progresses Phase IIb clinical trial as Nasdaq compliance plan advances.Quiver AI SummaryPsyence Biomedical Ltd. announced significant...

PBM : 3.18 (+29.27%)
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

PBM : 3.18 (+29.27%)
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

PBM : 3.18 (+29.27%)
Psyence Biomedical Ltd. Announces Share Consolidation Effective November 26, 2024

Psyence Biomedical Ltd. announced a 1-for-75 share consolidation effective November 26 to comply with Nasdaq listing requirements.Quiver AI SummaryPsyence Biomedical Ltd. announced the effective date of...

PBM : 3.18 (+29.27%)
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

PBM : 3.18 (+29.27%)
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

PBM : 3.18 (+29.27%)

Business Summary

Psyence Biomed is a life science biotechnology company which focus on natural psychedelics. The company's operating divisions include Psyence Production, Psyence Therapeutics and Psyence Function which operates in Canada, the United Kingdom, Southern Africa, Australia and a presence in the United States....

See More

Key Turning Points

3rd Resistance Point 5.50
2nd Resistance Point 4.87
1st Resistance Point 4.03
Last Price 3.18
1st Support Level 2.56
2nd Support Level 1.93
3rd Support Level 1.09

See More

52-Week High 323.25
Fibonacci 61.8% 200.35
Fibonacci 50% 162.38
Fibonacci 38.2% 124.41
Last Price 3.18
52-Week Low 1.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar